5-MeO-DPT: Difference between revisions
Tweaks. |
|||
(12 intermediate revisions by 11 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{cs1 config|name-list-style=vanc}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
Line 4: | Line 6: | ||
| verifiedrevid = 477224958 |
| verifiedrevid = 477224958 |
||
| IUPAC_name = N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine |
| IUPAC_name = N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine |
||
| image = 5-MeO-DPT |
| image = 5-MeO-DPT.svg |
||
| width = |
| width = 220 |
||
| image2 = 5-MeO-DPT.png |
|||
| width2 = 220 |
|||
<!--Clinical data--> |
<!--Clinical data--> |
||
Line 16: | Line 20: | ||
| legal_DE = NpSG |
| legal_DE = NpSG |
||
| legal_UK = Class A |
| legal_UK = Class A |
||
| legal_US = [[List of Schedule I drugs (US)|Schedule I (isomer of 5-MeO-DIPT)]] |
|||
| legal_US = |
|||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
Line 25: | Line 29: | ||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
Line 40: | Line 44: | ||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = AYW60P516B |
| UNII = AYW60P516B |
||
| synonyms = 5-Methoxy-''N'',''N''-dipropyltryptamine |
|||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=17 | H=26 | N=2 | O=1 |
| C=17 | H=26 | N=2 | O=1 |
||
| |
| SMILES = CCCN(CCC)CCc2c[nH]c1ccc(cc12)OC |
||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C17H26N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h6-7,12-13,18H,4-5,8-11H2,1-3H3 |
| StdInChI = 1S/C17H26N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h6-7,12-13,18H,4-5,8-11H2,1-3H3 |
||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChIKey = PNHPVNBKLQWBKH-UHFFFAOYSA-N |
| StdInChIKey = PNHPVNBKLQWBKH-UHFFFAOYSA-N |
||
<!--Physical data--> |
|||
| melting_point = 193 |
| melting_point = 193 |
||
| melting_high = 194 |
| melting_high = 194 |
||
}} |
}} |
||
'''5-MeO-DPT''' |
'''5-MeO-DPT''', also known as '''5-methoxy-''N'',''N''-dipropyltryptamine''', is a [[psychedelic drug|psychedelic]] and [[entheogen]]ic [[designer drug]] of the [[substituted tryptamine|tryptamine]] family related to [[dipropyltryptamine]] (DPT) and [[5-MeO-DMT]].<ref name="pmid6776558">{{cite journal | vauthors = Glennon RA, Young R, Rosecrans JA, Kallman MJ | title = Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities | journal = Psychopharmacology | volume = 68 | issue = 2 | pages = 155–8 | date = 1980 | pmid = 6776558 | doi = 10.1007/BF00432133 | s2cid = 1674481 }}</ref><ref>{{cite journal | vauthors = Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K | title = Identification and quantitative determination of 5-methoxy-N, N-di-n-propyltryptamine in urine by isotope dilution gas chromatography-mass spectrometry. | journal = Forensic Toxicology | date = June 2007 | volume = 25 | issue = 1 | pages = 1–7 | doi = 10.1007/s11419-006-0018-y | s2cid = 9906203 }}</ref><ref>{{cite journal | vauthors = Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H | title = Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry. | journal = Forensic Toxicology | date = January 2014 | volume = 32 | issue = 1 | pages = 154–61 | doi = 10.1007/s11419-013-0208-3 | s2cid = 25134125 }}</ref><ref name="pmid34026257">{{cite journal | vauthors = Pham DN, Chadeayne AR, Golen JA, Manke DR | title = 5-Meth-oxy-N,N-di-n-propyl-tryptamine (5-MeO-DPT): freebase and fumarate | journal = Acta Crystallographica Section E | volume = 77 | issue = Pt 5 | pages = 522–526 | date = May 2021 | pmid = 34026257 | pmc = 8100262 | doi = 10.1107/S2056989021003753 | bibcode = 2021AcCrE..77..522P }}</ref> |
||
==Chemistry== |
==Chemistry== |
||
The full chemical name is N-[2-(5-methoxy- |
The full chemical name is ''N''-[2-(5-methoxy-1''H''-indol-3-yl)ethyl]-''N''-propylpropan-1-amine. It is classified as a [[substituted tryptamine|tryptamine]] [[chemical derivative|derivative]]. |
||
==Effects== |
==Effects== |
||
Line 61: | Line 69: | ||
==Dosage== |
==Dosage== |
||
5-MeO-DPT is [[Wiktionary:oral|oral]]ly active, with 3-10 [[milligram|mg]] representing a fully effective dosage for most users. Effects begin within three hours, and usually last 4 hours. |
5-MeO-DPT is [[Wiktionary:oral|oral]]ly active, with 3-10 [[milligram|mg]] representing a fully effective dosage for most users. Effects begin within three hours, and usually last 4 hours. |
||
==Legality== |
|||
In the United States 5-MeO-DPT is considered a schedule 1 controlled substance as a positional isomer of [[5-Methoxy-N,N-diisopropyltryptamine]] (5-MeO-DiPT)<ref>{{cite web |url=https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf|title=Lists of: Scheduling Actions Controlled Substances Regulated Chemicals|publisher=U.S. Department of Justice|date=February 2023 |
|||
|access-date=5 March 2023}}</ref> |
|||
==See also== |
==See also== |
||
Line 82: | Line 94: | ||
[[Category:Psychedelic tryptamines]] |
[[Category:Psychedelic tryptamines]] |
||
[[Category:Designer drugs]] |
[[Category:Designer drugs]] |
||
{{hallucinogen-stub}} |
{{hallucinogen-stub}} |
Latest revision as of 19:30, 10 November 2024
Clinical data | |
---|---|
Other names | 5-Methoxy-N,N-dipropyltryptamine |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H26N2O |
Molar mass | 274.408 g·mol−1 |
3D model (JSmol) | |
Melting point | 193 to 194 °C (379 to 381 °F) |
| |
| |
(what is this?) (verify) |
5-MeO-DPT, also known as 5-methoxy-N,N-dipropyltryptamine, is a psychedelic and entheogenic designer drug of the tryptamine family related to dipropyltryptamine (DPT) and 5-MeO-DMT.[1][2][3][4]
Chemistry
[edit]The full chemical name is N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine. It is classified as a tryptamine derivative.
Effects
[edit]Little is known about the subjective effects of 5-MeO-DPT, but the nature of the compound is probably comparable to 5-MeO-DiPT, 5-MeO-DMT, or DPT, which are also psychedelic tryptamines/indoles. However, the duration of the above-mentioned drugs vary considerably.
Dosage
[edit]5-MeO-DPT is orally active, with 3-10 mg representing a fully effective dosage for most users. Effects begin within three hours, and usually last 4 hours.
Legality
[edit]In the United States 5-MeO-DPT is considered a schedule 1 controlled substance as a positional isomer of 5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT)[5]
See also
[edit]References
[edit]- ^ Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980). "Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities". Psychopharmacology. 68 (2): 155–8. doi:10.1007/BF00432133. PMID 6776558. S2CID 1674481.
- ^ Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K (June 2007). "Identification and quantitative determination of 5-methoxy-N, N-di-n-propyltryptamine in urine by isotope dilution gas chromatography-mass spectrometry". Forensic Toxicology. 25 (1): 1–7. doi:10.1007/s11419-006-0018-y. S2CID 9906203.
- ^ Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H (January 2014). "Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry". Forensic Toxicology. 32 (1): 154–61. doi:10.1007/s11419-013-0208-3. S2CID 25134125.
- ^ Pham DN, Chadeayne AR, Golen JA, Manke DR (May 2021). "5-Meth-oxy-N,N-di-n-propyl-tryptamine (5-MeO-DPT): freebase and fumarate". Acta Crystallographica Section E. 77 (Pt 5): 522–526. Bibcode:2021AcCrE..77..522P. doi:10.1107/S2056989021003753. PMC 8100262. PMID 34026257.
- ^ "Lists of: Scheduling Actions Controlled Substances Regulated Chemicals" (PDF). U.S. Department of Justice. February 2023. Retrieved 5 March 2023.
External links
[edit]